# Ipamorelin CJC-1295: The Common Research Stack Explained > Ipamorelin cjc-1295 is the most common GHRH+GHRP research stack. The cited pharmacology behind the pairing, what each peptide does, and why the combination itself has never been tested. A GHRH analog plus a GHRP — the most-discussed pairing in research-use communities, with its rationale read straight from single-agent pharmacology. ## The gist The ipamorelin cjc-1295 pairing is the most common "stack" people ask about, and the reason it makes pharmacological sense is simple: the two peptides release growth hormone by two different doors that work better together than either alone. Ipamorelin works on the ghrelin receptor; CJC-1295 is a long-acting version of the body's own growth-hormone-releasing hormone (GHRH) and works on the GHRH receptor. Combining a GHRH-type drug with a ghrelin-type drug produces more GH than either by itself — a synergy documented across the research literature. But here is the line this page keeps in plain view: that synergy is read off each drug's *separate* studies. The specific combination of ipamorelin and CJC-1295 has never been tested in a trial, for any outcome. The case for it is mechanistic and inferred, not demonstrated. ## What each peptide contributes Ipamorelin is a selective growth hormone secretagogue: it acts on the ghrelin / GHS-R1a receptor to release a GH pulse, cleanly, without raising cortisol or prolactin [1]. Its half-life in people is about 2 hours, and the GH it triggers is a single pulse peaking near 40 minutes [2]. CJC-1295 is a long-acting GHRH analog: in healthy adults, a single subcutaneous dose produced dose-dependent 2- to 10-fold GH increases for more than six days and a 1.5- to 3-fold sustained rise in IGF-1, while preserving the natural pulsatile pattern of secretion [11]. In stack terms, the short, sharp ipamorelin pulse and the long, sustained CJC-1295 elevation are pharmacologically complementary — one acute, one prolonged, by two distinct receptors. ## Why the two pathways synergize The synergy is a class property, well documented at the receptor level. A comprehensive review established that growth-hormone-releasing peptides act synergistically with GHRH and are partially resistant to the inhibitory signals — glucose, free fatty acids, somatostatin — that nearly abolish a GHRH pulse on its own; that resistance is exactly what lets a GHRP augment a GHRH-driven release [7]. A neuroendocrine review adds the circuit: ghrelin and GHS-R1a agonists facilitate GHRH release by inhibiting somatostatin and synergize at the pituitary, producing dual amplification when paired with a GHRH analog [9]. In a direct animal test, low-dose GHRP-6 combined with GHRH produced a higher GH peak and area-under-curve than GHRH alone in lambs (p<0.05) [10]. Studies [7], [9], and [10] use related GHRPs or review data to establish the class principle — the mechanism that the ipamorelin cjc-1295 pairing borrows. ## What is CJC 1295 ipamorelin What is CJC 1295 ipamorelin? It is the combination of two separate research peptides commonly supplied and discussed together: CJC-1295, a long-acting GHRH analog, and ipamorelin, a selective ghrelin-receptor GHRP. The two are paired because their mechanisms are complementary — a sustained GHRH-driven elevation plus a clean GHS-R1a pulse [11] [1]. It is not a single approved product, not a tested formulation, and not a drug with an approved indication. Neither component is FDA-approved, and the combination has never been evaluated in a clinical trial [3]. ## Is CJC-1295 ipamorelin safe, and does it work Is CJC-1295 ipamorelin safe? There is no controlled human safety study of the combination, so the honest answer is that combination-specific safety is unknown — the safety record has to be assembled from each peptide's separate, limited data and the class-level cautions on the [Ipamorelin effects](/effects) page. Does CJC-1295 ipamorelin work? Each component changes GH and IGF-1 in single-agent studies [11] [2], so the pharmacology is real; but "works" in the sense of a proven human outcome from the *combination* has never been demonstrated in a trial [3]. The pairing is supported by mechanism, not by combination outcome data — a distinction this digest keeps deliberately sharp. A related question some readers ask is whether the stack can be extended with sermorelin; that comparison is covered on the [ipamorelin vs sermorelin](/vs-sermorelin) page. --- A Carbon-plain reading of the ipamorelin record: the selective GH pulse and the ~2-hour human half-life logged where the studies confirm them, the failed Phase 2 trial and the blank long-term-safety line set in equal type, and the CJC-1295 stack read as class pharmacology rather than a tested product — the word 'safe' here naming a question we keep open, with no clinic behind the page and nothing dosed, compounded, prescribed, or sold.